Magenta Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 22.95 million compared to USD 17.49 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.36 a year ago.